190.27 0.00 (0.00%)
After hours: 4:14PM EST
|Bid||151.12 x 1100|
|Ask||202.50 x 1000|
|Day's Range||189.58 - 193.72|
|52 Week Range||154.88 - 256.22|
|Beta (3Y Monthly)||1.48|
|PE Ratio (TTM)||51.20|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||247.80|
The kind of high-quality characteristics that we seek in Premier--companies with high returns on invested capital and sustainable competitive advantages--are usually trading more closely to their full valuation. It can take a long time for what we think are high-quality small-caps to enter a favorable valuation range. Warning! GuruFocus has detected 1 Warning Sign with FCAU.
Based on IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) earnings update in September 2018, analyst consensus outlook appear cautiously optimistic, as a 21% increase in profits is expected in the upcoming year, compared Read More...
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
How's Dentsply Positioned in November? Dentsply Sirona’s (XRAY) cost of products sold increased marginally from $450.2 million in the third quarter of 2017 to $452.3 million in the third quarter. For fiscal 2018 and 2019, Dentsply’s gross margins are expected to be 55.04% and 55.29%, respectively—compared to its gross margins of 54.80% for fiscal 2017.
Among the 15 analysts covering Dentsply Sirona (XRAY) in November, five analysts gave a “buy” or a higher recommendation, while ten analysts gave a “hold” recommendation. The mean rating for Dentsply stock is 2.53 with a target price of $46.73, which implies an upside potential of 28% over the closing price of $36.51 on November 23. Peers’ ratings
Dentsply Sirona (XRAY) is a global manufacturer of professional dental products and technologies. Dentsply operates in two business segments—the Consumables and Technologies segment and the Equipment segment. Sales from the Technologies and Equipment segment, which includes dental implants, imaging systems, treatment centers, and consumable medical device products, decreased from $558.5 million in the third quarter of 2017 to $495.2 million in the third quarter.
Right now it's pretty much IDEXX Laboratories Inc. (IDEXX) and everyone else. Warning! GuruFocus has detected 6 Warning Signs with AAT. One of the reasons is that people are buying more pet health insurance.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Foot Locker Inc. FL : "I've got to tell you, I think Foot Locker's OK, but it would've been a lot better in the $30s. Arista Networks Inc. ANET : "I think that they are very good and [CEO] Jayshree Ullal, whom I would love to have back on the show, is a brilliant manager.
The big shareholder groups in IDEXX Laboratories Inc (NASDAQ:IDXX) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...
The Westbrook, Maine-based company said it had net income of $1.05 per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
WESTBROOK, Maine , Nov. 1, 2018 /PRNewswire/ -- Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% ...
IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.